{"id": 998345, "name": "Share of countries testing >80% of confirmed urinary tract infections for antibiotic susceptibility", "unit": "%", "createdAt": "2024-11-21T16:31:14.000Z", "updatedAt": "2025-02-12T17:22:42.000Z", "coverage": "", "timespan": "2016-2022", "datasetId": 6807, "shortUnit": "%", "columnOrder": 0, "shortName": "share_ctas_with_reported_bcis_with_ast__gt__80_bcis_urinary_tract", "catalogPath": "grapher/antibiotics/2024-11-15/testing_coverage/testing_coverage#share_ctas_with_reported_bcis_with_ast__gt__80_bcis_urinary_tract", "descriptionShort": "Share of countries testing >80% bacteriologically confirmed urinary tract infections for antibiotic susceptibility.", "type": "float", "dataChecksum": "12426014456009768598", "metadataChecksum": "6227700336399507066", "datasetName": "Global Antimicrobial Resistance and Use Surveillance System (GLASS) - Testing Coverage", "updatePeriodDays": 365, "datasetVersion": "2024-11-15", "nonRedistributable": false, "display": {"name": "Urinary tract infections", "unit": "%", "shortUnit": "%"}, "schemaVersion": 2, "presentation": {"topicTagsLinks": ["Antibiotics & Antibiotic Resistance"]}, "descriptionKey": ["Escheria coli infections are tested for their susceptibility to fluoroquinolone antibiotics, sulfonamides and trimethoprim antibiotics and third-generation cephalosporin antibiotics.", "Klebsiella pneumoniae infections are tested for their susceptibility to fluoroquinolone antibiotics, sulfonamides and trimethoprim antibiotics and third-generation cephalosporin antibiotics."], "dimensions": {"years": {"values": [{"id": 2016}, {"id": 2017}, {"id": 2018}, {"id": 2019}, {"id": 2020}, {"id": 2021}, {"id": 2022}]}, "entities": {"values": [{"id": 277958, "name": "African Region (WHO)", "code": null}, {"id": 355, "name": "World", "code": "OWID_WRL"}, {"id": 369119, "name": "Eastern Mediterranean (WHO)", "code": null}, {"id": 277955, "name": "European Region (WHO)", "code": null}, {"id": 277957, "name": "Region of the Americas (WHO)", "code": null}, {"id": 277953, "name": "South-East Asia Region (WHO)", "code": null}, {"id": 277952, "name": "Western Pacific Region (WHO)", "code": null}]}}, "origins": [{"id": 2045, "title": "Global Antimicrobial Resistance and Use Surveillance System (GLASS) - Testing Coverage", "description": "GLASS provides a standardized approach to the collection, analysis, interpretation and sharing of data by countries and seeks to actively support capacity building and monitor the status of existing and new national surveillance systems. Furthermore, GLASS promotes a shift from surveillance approaches based solely on laboratory data to a system that includes epidemiological, clinical, and population-level data. GLASS has been conceived to progressively incorporate data from surveillance of AMR in humans, such as monitoring of resistance and the use of antimicrobial medicines, including AMR in the food chain and in the environment.", "producer": "World Health Organization", "citationFull": "Global AMR data - Global Antimicrobial Resistance and Use Surveillance System (GLASS), World Health Organization (2024)", "attributionShort": "WHO", "urlMain": "https://worldhealthorg.shinyapps.io/glass-dashboard/_w_679389fb/#!/amr", "dateAccessed": "2024-11-15", "datePublished": "2024-09-16", "license": {"url": "https://www.who.int/about/policies/terms-of-use", "name": "\u00a9 2024 WHO"}}]}